{
    "eid": "2-s2.0-85133473592",
    "title": "Bevacizumab Eye Drops Vs. Intra-meibomian Gland Injection of Bevacizumab for Meibomian Gland Dysfunction-Associated Posterior Blepharitis",
    "cover-date": "2022-06-10",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Medicine (all)",
            "@code": "2700",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "bevacizumab",
        "lid hygiene",
        "lid margin telangiectasia",
        "meibomian gland dysfunction (MGD)",
        "vascular endothelial growth factor (VEGF)"
    ],
    "authors": [
        "Chitchanok Tantipat",
        "Ngamjit Kasetsuwan",
        "Patraramon Chotikkakamthorn",
        "Krit Pongpirul"
    ],
    "citedby-count": 0,
    "ref-count": 37,
    "ref-list": [
        "Prevalence of dry eye in Bangkok, Thailand",
        "Association between symptoms and signs of dry eye among an elderly Chinese population in Taiwan: the Shihpai eye study",
        "The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee",
        "Efficacy of azithromycin eyedrops for individuals with meibomian gland dysfunction-associated posterior blepharitis",
        "Posterior blepharitis and associated potential factors: a study among pregnant women",
        "The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction",
        "Compliance and subjective patient responses to eyelid hygiene",
        "Conservative treatment of meibomian gland dysfunction",
        "Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization",
        "Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study",
        "Efficacy of intra-meibomian gland injection of the anti-VEGF agent bevacizumab for the treatment of meibomian gland dysfunction with lid-margin vascularity",
        "Development of definitive and reliable grading scales for meibomian gland dysfunction",
        "Safety of antivascular endothelial growth factor administration in the ocular anterior segment in pterygium and neovascular glaucoma treatment: systematic review and meta-analysis",
        "Reliability and validity of the ocular surface disease index",
        "How red is a white eye? Clinical grading of normal conjunctival hyperaemia",
        "Grading of corneal and conjunctival staining in the context of other dry eye tests",
        "Meibography: a Japanese perspective",
        "Efficiency and safety of subconjunctival injection of anti-VEGF agent - bevacizumab - in treating dry eye",
        "Efficacy of topical bevacizumab 0",
        "Inflammatory cytokines regulate secretion of VEGF and chemokines by human conjunctival fibroblasts: role in dysfunctional tear syndrome",
        "Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease",
        "Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas",
        "Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention",
        "VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment",
        "Evidence of corneal lymphangiogenesis in dry eye disease: a potential link to adaptive immunity?",
        "Dry eye disease: an immune-mediated ocular surface disorder",
        "Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease",
        "VEGF and its receptor-2 involved in neuropathic pain transmission mediated by P2X2(/)3 receptor of primary sensory neurons",
        "Lifitegrast ophthalmic solution 5",
        "Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study Group",
        "Meibum expressibility improvement as a therapeutic target of intense pulsed light treatment in meibomian gland dysfunction and its association with tear inflammatory cytokines",
        "Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction",
        "Morphological evaluation of meibomian glands using noncontact infrared meibography",
        "Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study",
        "A comparison of cyclosporine 0",
        "Evaluation of lipid layer thickness measurement of the tear film as a diagnostic tool for meibomian gland dysfunction",
        "Persistence of efficacy of 0"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Ratchadapiseksompotch Fund",
        "Faculty of Medicine, Chulalongkorn University"
    ]
}